Recombinant Human SNAP25 Protein，His

Shiga toxin 2B (Stx2B) is a variant of the Shiga toxin produced by certain pathogenic strains of Escherichia coli, particularly Shiga toxin-producing E. coli (STEC) such as O157:H7. This toxin is notorious for causing severe gastrointestinal disease, including hemorrhagic colitis and hemolytic uremic syndrome (HUS), which can lead to acute kidney failure, particularly in vulnerable populations like children and the elderly. The Stx2B subunit, part of the heterohexameric structure of the toxin, plays a crucial role in the binding of the toxin to host cells, facilitating the internalization of the enzymatically active Stx2A subunit. Research into recombinant Stx2B has gained momentum due to its potential applications in vaccine development, therapeutic interventions, and as a tool for understanding the pathogenesis of STEC infections. Recombinant techniques allow for the production of Stx2B in controlled settings, providing a safer model for studying its biological properties and interactions with the immune system. Furthermore, the incorporation of Stx2B into vaccine formulations could enhance immune responses, offering protective measures against STEC infections. Understanding the structural and functional aspects of Stx2B through recombinant technologies is essential for the development of effective diagnostics and therapeutics targeting Shiga toxin-related diseases. Hence, research focused on recombinant Stx2B holds significant promise for improving public health outcomes related to STEC infections and enhancing our comprehension of toxin-mediated cellular mechanisms.